124 related articles for article (PubMed ID: 27222271)
1. Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects.
Spiegelstein O; Stevens J; Van Gerven J; Nathan PJ; Maynard JP; Mayleben DW; Hellriegel E; Yang R
J Psychopharmacol; 2016 Oct; 30(10):983-93. PubMed ID: 27222271
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.
Baakman AC; Zuiker R; van Gerven JMA; Gross N; Yang R; Fetell M; Gershon A; Gilgun-Sherki Y; Hellriegel E; Spiegelstein O
Br J Clin Pharmacol; 2019 May; 85(5):970-985. PubMed ID: 30710391
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
Othman AA; Haig G; Florian H; Locke C; Zhang J; Dutta S
Br J Clin Pharmacol; 2013 May; 75(5):1299-311. PubMed ID: 23016924
[TBL] [Abstract][Full Text] [Related]
4. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
Russell T; Stoltz M; Weir S
Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H
Venail F; Attali P; Wersinger E; Gomeni R; Poli S; Schmerber S
Br J Clin Pharmacol; 2018 Dec; 84(12):2836-2848. PubMed ID: 30152527
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
10. The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects.
Kollmeier A; Francke K; Chen B; Dunford PJ; Greenspan AJ; Xia Y; Xu XL; Zhou B; Thurmond RL
J Pharmacol Exp Ther; 2014 Jul; 350(1):181-7. PubMed ID: 24817035
[TBL] [Abstract][Full Text] [Related]
11. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
[TBL] [Abstract][Full Text] [Related]
12. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.
Raddatz R; Hudkins RL; Mathiasen JR; Gruner JA; Flood DG; Aimone LD; Le S; Schaffhauser H; Duzic E; Gasior M; Bozyczko-Coyne D; Marino MJ; Ator MA; Bacon ER; Mallamo JP; Williams M
J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J
J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.
Hudkins RL; Becknell NC; Lyons JA; Aimone LD; Olsen M; Haltiwanger RC; Mathiasen JR; Raddatz R; Gruner JA
Eur J Med Chem; 2015 May; 95():349-56. PubMed ID: 25827402
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers.
Martin DE; Blum R; Doto J; Galbraith H; Ballow C
Clin Pharmacokinet; 2007; 46(7):589-98. PubMed ID: 17596104
[TBL] [Abstract][Full Text] [Related]
17. The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.
Othman AA; Haig G; Florian H; Locke C; Gertsik L; Dutta S
Br J Clin Pharmacol; 2014 Jun; 77(6):965-74. PubMed ID: 24215171
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Lowe SL; Wong CJ; Witcher J; Gonzales CR; Dickinson GL; Bell RL; Rorick-Kehn L; Weller M; Stoltz RR; Royalty J; Tauscher-Wisniewski S
J Clin Pharmacol; 2014 Sep; 54(9):968-78. PubMed ID: 24619932
[TBL] [Abstract][Full Text] [Related]
20. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.
Hoch M; van Gorsel H; van Gerven J; Dingemanse J
J Clin Pharmacol; 2014 Sep; 54(9):979-86. PubMed ID: 24691844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
